Treatment of lung infection in patients with cystic fibrosis: current and future strategies

Gerd Döring; Patrick Flume; Harry Heijerman; J Stuart Elborn; Consensus Study Group

doi:10.1016/j.jcf.2012.10.004

Treatment of lung infection in patients with cystic fibrosis: current and future strategies

Gerd Döring, Patrick Flume, Harry Heijerman, J Stuart Elborn, Consensus Study Group

322 Citations (Scopus)

Abstract

In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main cause of death. Treatment of lung disease to reduce the impact of infection, inflammation and subsequent lung injury is therefore of major importance. Here we discuss the present status of antibiotic therapy for the major pathogens in CF airways, including prophylaxis against infection, eradication of early infection, suppression of chronic infection, and the treatment of infective exacerbations. We outline measures to optimize maintenance treatment for infection in the light of novel antibiotic drug formulations. We discuss new developments in culture-independent microbiological diagnostic techniques and the use of tools for monitoring the success of antibiotic treatment courses. Finally, cost-effectiveness analyses for antibiotic treatment in CF patients are discussed.

Original language	English
Journal	Journal of Cystic Fibrosis
Volume	11
Issue number	6
Pages (from-to)	461-479
Number of pages	19
ISSN	1569-1993
DOIs	https://doi.org/10.1016/j.jcf.2012.10.004
Publication status	Published - Dec 2012

Keywords

Anti-Bacterial Agents
Cystic Fibrosis
Humans
Pneumonia, Bacterial
Pseudomonas Infections
Pseudomonas aeruginosa

Access to Document

10.1016/j.jcf.2012.10.004

Cite this

@article{97a48ac074554241bef8875d5893c99d,

title = "Treatment of lung infection in patients with cystic fibrosis: current and future strategies",

abstract = "In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main cause of death. Treatment of lung disease to reduce the impact of infection, inflammation and subsequent lung injury is therefore of major importance. Here we discuss the present status of antibiotic therapy for the major pathogens in CF airways, including prophylaxis against infection, eradication of early infection, suppression of chronic infection, and the treatment of infective exacerbations. We outline measures to optimize maintenance treatment for infection in the light of novel antibiotic drug formulations. We discuss new developments in culture-independent microbiological diagnostic techniques and the use of tools for monitoring the success of antibiotic treatment courses. Finally, cost-effectiveness analyses for antibiotic treatment in CF patients are discussed.",

keywords = "Anti-Bacterial Agents, Cystic Fibrosis, Humans, Pneumonia, Bacterial, Pseudomonas Infections, Pseudomonas aeruginosa",

author = "Gerd D{\"o}ring and Patrick Flume and Harry Heijerman and Elborn, {J Stuart} and Niels H{\o}iby and {Consensus Study Group}",

year = "2012",

month = dec,

doi = "10.1016/j.jcf.2012.10.004",

language = "English",

volume = "11",

pages = "461--479",

journal = "Journal of Cystic Fibrosis",

issn = "1569-1993",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Treatment of lung infection in patients with cystic fibrosis

T2 - current and future strategies

AU - Döring, Gerd

AU - Flume, Patrick

AU - Heijerman, Harry

AU - Elborn, J Stuart

AU - Høiby, Niels

AU - Consensus Study Group

PY - 2012/12

Y1 - 2012/12

N2 - In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main cause of death. Treatment of lung disease to reduce the impact of infection, inflammation and subsequent lung injury is therefore of major importance. Here we discuss the present status of antibiotic therapy for the major pathogens in CF airways, including prophylaxis against infection, eradication of early infection, suppression of chronic infection, and the treatment of infective exacerbations. We outline measures to optimize maintenance treatment for infection in the light of novel antibiotic drug formulations. We discuss new developments in culture-independent microbiological diagnostic techniques and the use of tools for monitoring the success of antibiotic treatment courses. Finally, cost-effectiveness analyses for antibiotic treatment in CF patients are discussed.

AB - In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main cause of death. Treatment of lung disease to reduce the impact of infection, inflammation and subsequent lung injury is therefore of major importance. Here we discuss the present status of antibiotic therapy for the major pathogens in CF airways, including prophylaxis against infection, eradication of early infection, suppression of chronic infection, and the treatment of infective exacerbations. We outline measures to optimize maintenance treatment for infection in the light of novel antibiotic drug formulations. We discuss new developments in culture-independent microbiological diagnostic techniques and the use of tools for monitoring the success of antibiotic treatment courses. Finally, cost-effectiveness analyses for antibiotic treatment in CF patients are discussed.

KW - Anti-Bacterial Agents

KW - Cystic Fibrosis

KW - Humans

KW - Pneumonia, Bacterial

KW - Pseudomonas Infections

KW - Pseudomonas aeruginosa

U2 - 10.1016/j.jcf.2012.10.004

DO - 10.1016/j.jcf.2012.10.004

M3 - Journal article

C2 - 23137712

SN - 1569-1993

VL - 11

SP - 461

EP - 479

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

IS - 6

ER -

Treatment of lung infection in patients with cystic fibrosis: current and future strategies

Abstract

Keywords

Access to Document

Fingerprint

Cite this